Archived File The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be outdated. See the OER Public Archive Home Page for more details about archived files.archivedOER Public Archive Home Page

2 PEER REVIEW ADVISORY COMMITTEE Update on New CSR Realignments Basic Oncology and Bioengineering Don Schneider National Institutes of Health U.S. Department of Health and Human Services February 1, 2010

Continuous evolution/alignment of study sections is necessary Science changes CSR is committed to assessment Study section size matters – too small/too large [Fewer than 50 applications Is a problem] 3

Three goals to consider Look at recent reorganizations Examine proposed guideline adjustments for Oncology 1 – Basic Translational (OBT) IRG Re-examine Microscopic Imaging study section 4

Cell Biology merged study sections 2009/052010/05 Cell Structure Nuclear & Cytoplasmic & Function41Struct, Functn, & Dynam Nuclear Dynam 67 & Transport45Cellular Signaling & Regulatory Systems58Systems84 Subtotal applctns 5

Digestv, Kidney, & Urologcl Sys merged study sections 2009/ /05 Gastrointestinal Cell & Molecular Biology41 Gastrointestinal Mucosal Pathobiology53 Pathobiology 56 Hepatobiliary Pathophysiology 64 Pathophysiology 78 Clinical &Clinical,Integrative Gastrointestinal& Molecular Pathobiology46Gastroenterology 68 Subtotal

Bioengineering merged panels 2009/052010/05 Biodata Management & Analysis40 & Analysis88 SEP28 Modeling & Analysis Of Biological Systems39 Systems72 Microscopic Imaging20 Imaging27 Subtotal

Interim analysis of realignments is positive Workloads improve (except Micros Imaging) Science and fairness of review are probably better CSR needs metric/tool to measure scientific impact 8

Translational and Clinical Sciences Cardiovascular and Respiratory Sciences Surgical Sciences, Biomedical Imaging and Bioengineering Musculoskeletal, Oral & Skin Sciences Oncology: Translational Clinical Vascular and Hematology Physiological and Pathological Sciences Endocrinology, Metabolism, Nutrition & Reproductive Sciences Immunology Infectious Diseases & Microbiology Digestive, Kidney & Urological Systems Neuroscience, Development and Aging Brain Disorders & Clinical Neuroscience Molecular, Cellular & Developmental Neuroscience Integrative, Functional & Cognitive Neuroscience Emerging Technologies & Training in Neuroscience Biology of Development & Aging Biobehavioral & Behavioral Processes Risk, Prevention& Health Behavior Population Sciences & Epidemiology Healthcare Delivery & Methodologies AIDS & AIDS Related Research AIDS, Behavioral and Population Sciences Basic and Integrative Biological Sciences Biological Chemistry & Macromolecular Biophysics Bioengineering Sciences & Technologies Genes, Genomes & Genetics Oncology: Basic Translational Cell Biology Interdisciplinary Molecular Sciences & Training CSR formed five review divisions, January 2009

Oncology 1 – Basic & Translational IRG was established and reviewed Split ONC to form OBT & OTC January 2009 Collected feedback from reviewers two cycles (October and February meetings) Discussed feedback with Chairs (Chief and DD) Reviewed by CSR Director et al September 23, 2009 [Chief – Cathleen Cooper] 10

Realignments are proposed for OBT study sections For emerging trends, clarity of scientific scope, and workload balance, guideline adjustments are proposed: Cancer Molecular Pathology study section (CAMP) –about 110 applications a cycle; focuses on oncogenes and tumor suppressors; move telomeres and epigenomics Cancer Genetics study section (CG) – about 75 applications a cycle; focuses on chromosomal integrity and stability; add telomeres and epigenomics (would fit well) Cancer Etiology study section (CE) – about 90 applications a cycle; focuses on DNA repair and environmental carcinogenesis; move epigenomics unless focus is environmental Estimated result: about 95, 90, and 90 applications 11

Bioengineering Sciences and Technologies IRG was formed in 2004 Regular Study Sections Biodata Management and Analysis (BDMA) Biomaterials and Biointerfaces (BMBI) Gene and Drug Delivery Systems (GDD) Instrumentation Systems and Development (ISD) Modeling and Analysis of Biological Systems (MABS) Microscopic Imaging (MI) Nanotechnology (NANO) [Chief – George Chacko] 12

Steps to realign were taken a year ago Original study sections were hybrids in that R01s and R43s were reviewed together – no longer possible BDMA & MI were small, about 50 applications each Via Working Group and PRAC, BDMA was combined with a software SEP and scope of MI was expanded 13

2009 Realignment worked for BDMA, not for MI 14

Microscopic Imaging and Spectroscopy The study section focuses on review of applications on techniques and instrumentation for microscopic visualization of molecules, organelles, and model systems Development and improvement of microscopic imaging and spectroscopy Development of imaging tools/software Image acquisition and analysis, including single particle 15

Instrumentation Systems and Development shares interests with Microscopic Imaging Optical and spectroscopic instrumentation Microfabrication Automation and integration Sensing of single cells 16

MIS, ISD, & EBT share interests Microscopic Imaging and Spectroscopy, in BST, focus is to develop techniques to visualize molecules, organelles, and cells Instrumentation and Systems Development, in BST, focus is to develop instrumentation for biological research Enabling Bioanalytical and Biophysical Technologies, in BCMB, focus is development of bioanalytical tools to probe molecules 17

Options presented to Working Group [Working within the Bioengineering IRG] Terminate MIS Merge MIS with ISD Expand the scope of MIS 18

Bioengineering Working Group #2 met January 2010 ROSTER Wah Chiu, PhD (Baylor College of Medicine) Robert M Dickson, PhD (Georgia Institute of Technology) Michael Gilson, MD, PhD (University of Maryland) Enrico Gratton, PhD (University of California Irvine) Jerome Mertz, PhD (Boston University) Stephen C Miller, PhD (University of Massachusetts Worcester) Amy Palmer, PhD (University of Colorado Boulder) Peter Sorger, PhD (Massachusetts Institute of Technology) Shankar Subramaniam, PhD (University of California San Diego) Stephen Wong, PhD (Cornell University Weill) Xiaowei Zhuang, PhD (Harvard University) NIH: James Deatherage, PhD (NIGMS); Catherine Lewis, PhD (NIGMS); George Chacko, PhD (CSR); Don Schneider, PhD (CSR) 19

Working Group Expressed Preferences Terminate Microscopic Imaging - WG least enthusiasm, integrated basic imaging panel has value, will grow Merge MIS, principally with Instrumentation and Systems Development - WG medium enthusiasm Expand scope and continue Microscopic Imaging - WG considerable enthusiasm 20

Should MI be continued? Element of “Been there, done that” Related issues - EBT study section - IMST IRG 21

CSR created Interdisciplinary Molecular Sciences & Training IRG January 2009 IMST uses SEPs to review all fellowship and small business applications for Basic & Integrative Biological Sciences (basic oncology, bio- chemistry/biophysics, bioengineering, cell biology, and genetics) IMST uses SEPs to review interdisciplinary special applications, e.g., some P01s, P41s, and S10s IMST was recently chartered, with understanding that it would form a regular, chartered study section [Chief – Ross Shonat] 22

Taking a bolder, broader view EBT averages about 60 applications a round MI averages about 25 applications a round EBT and MI have complementary interests IMST IRG needs a chartered study section = 85, close to ideal Create EBIT, Enabling Bioanalytical and Imaging Technologies 23

PRAC input sought Oncology 1 – Basic Translational IRG (OBT) Move telomeres and epigenomics from Cancer Molecular Pathology to Cancer Genetics Move some epigenomics from Cancer Etiology to Cancer Genetics Microscopic Imaging and Spectroscopy Allow more time for growth, OR Merge with Enabling Bioanalytical and Biophysical Technologies and move to Interdisciplinary Molecular Sciences and Training IRG 24

Discussion